Medifast presented Trilivy data and Medifast stock costs EUR 10.16

Published on 10/08/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medifast stock was at EUR 10.16 on October 8, 2026 versus EUR 10.22. Trilivy documented 98.00 percent lean mass retention.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast (ISIN US58470H1014) was trading at EUR 10.16 at Lang & Schwarz on October 8, 2026 at 1:31 p.m. CEST, down 0.59 percent versus the prior close of EUR 10.22. The company had presented new Trilivy metabolic-health data on October 6, 2026, giving the stock a fresh strategic reference point.

Trilivy adds two measurable claims

According to GlobeNewswire on October 6, 2026, Medifast said its Reset 5 & 1 Plan documented 98.00 percent lean mass retention and a 14.00 percent reduction in visceral fat at 16 weeks. The release identified five drivers of weight regain and described Trilivy's Burn, Preserve and Protect framework as a three-part response.

Revenue beat met a shrinking coach base

In the second quarter of 2026, revenue reached USD 76.38 million, down 27.60 percent from USD 105.60 million a year earlier, while the loss per share narrowed to USD 0.28 from a consensus loss of USD 0.67, according to Zacks. The operating trade-off was sharp: active earning coaches fell 48.70 percent to 11,700, but average revenue per active earning coach rose 41.00 percent to USD 6,529.

What does the launch mean for margins?

The near-term answer is a wide operating range. Management expects third-quarter 2026 revenue of USD 60 million to USD 80 million and a loss per share of USD 0.15 to USD 0.65, excluding one-time Catalyst cost-savings charges, while fiscal-year 2026 revenue guidance remains USD 270 million to USD 300 million, according to Zacks. The company expects progress toward profitability beginning in the fourth quarter of 2026, making coach retention and productivity the key operating tension.

Three milestones frame the reset

On August 3, 2026, Medifast reported second-quarter revenue of USD 76.38 million, according to Zacks. On September 17, 2026, the company marked 20 years as a publicly traded business at the New York Stock Exchange, according to Trilivy. On October 6, 2026, Medifast presented the 98.00 percent lean mass retention and 14.00 percent visceral-fat reduction figures in its Trilivy release.

Next reporting dates are set

The next earnings call is listed for November 2, 2026, and the next earnings report for November 9, 2026, according to ToAlpha. Those dates place the next test of the coach-productivity strategy within the fourth-quarter profitability timetable.

MED stock holds a narrow daily range

Medifast stock was trading at EUR 10.16 at Lang & Schwarz on October 8, 2026 at 1:31 p.m. CEST, minus 0.59 percent versus the prior close of EUR 10.22 on October 7, 2026. On the NYSE, the company had a market capitalization of USD 127.2 million and a 52-week range of USD 9.22 to USD 14.15 as of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Medifast stock.